Open Access

RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)

  • Authors:
    • Yuping Liu
    • Ting Liu
    • Tiantian Lei
    • Dingding Zhang
    • Suya Du
    • Lea Girani
    • Dandan Qi
    • Chen Lin
    • Rongsheng Tong
    • Yi Wang
  • View Affiliations

  • Published online on: June 14, 2019     https://doi.org/10.3892/ijmm.2019.4244
  • Pages: 771-786
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduction from receptor‑interacting serine/threonine kinase (RIP) 1 to RIP3 (hereafter called RIP1/RIP3). However, RIP3‑dependent cell death would be a more precise definition of necroptosis. RIP3 is indispensable for necroptosis, while RIP1 is not consistently involved in the signal transduction. Notably, deletion of RIP1 even promotes RIP3‑mediated necroptosis under certain conditions. Necroptosis was previously thought as an alternate process of cell death in case of apoptosis inhibition. Currently, necroptosis is recognized to serve a pivotal role in regulating various physiological processes. Of note, it mediates a variety of human diseases, such as ischemic brain injury, immune system disorders and cancer. Targeting and inhibiting necroptosis, therefore, has the potential to be used for therapeutic purposes. To date, research has elucidated the suppression of RIP1/RIP3 via effective inhibitors and highlighted their potential application in disease therapy. The present review focused on the molecular mechanisms of RIP1/RIP3‑mediated necroptosis, explored the functions of RIP1/RIP3 in necroptosis, discussed their potential as a novel therapeutic target for disease therapy, and provided valuable suggestions for further study in this field.
View Figures
View References

Related Articles

Journal Cover

September-2019
Volume 44 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, Qi D, Lin C, Tong R, Wang Y, Wang Y, et al: RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review). Int J Mol Med 44: 771-786, 2019
APA
Liu, Y., Liu, T., Lei, T., Zhang, D., Du, S., Girani, L. ... Wang, Y. (2019). RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review). International Journal of Molecular Medicine, 44, 771-786. https://doi.org/10.3892/ijmm.2019.4244
MLA
Liu, Y., Liu, T., Lei, T., Zhang, D., Du, S., Girani, L., Qi, D., Lin, C., Tong, R., Wang, Y."RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)". International Journal of Molecular Medicine 44.3 (2019): 771-786.
Chicago
Liu, Y., Liu, T., Lei, T., Zhang, D., Du, S., Girani, L., Qi, D., Lin, C., Tong, R., Wang, Y."RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)". International Journal of Molecular Medicine 44, no. 3 (2019): 771-786. https://doi.org/10.3892/ijmm.2019.4244